Description
Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).
Obstructive hypertrophic cardiomyopathy (oHCM) is a condition in which the heart muscle thickens abnormally, obstructing blood flow and causing symptoms like shortness of breath, chest pain, and fatigue.
In India, BMS obtained an import license from the CDSCO (Central Drugs Standard Control Organization) in March 2025 to bring in Kopozgo.
The approval was supported by results from two Phase 3 clinical trials, EXPLORER-HCM and VALOR-HCM, which showed that Mavacamten had consistent efficacy and an acceptable safety profile in patients with oHCM.
Contact Sourcing Facilitation Team
Contact Name: Mr. Tarun Garg
Address: 60/4, Yusaf Sarai, Near Indian Oil Corp., New Delhi – 110 016 (India)
Mobile/WhatsApp. 9891296838.
Email: support@southdelhipharma.com, southdelhipharma@gmail.com
Get Access Kopozgo (mavacamten) Capsules In India on request.
Kopozgo Capsules a prescription medicine is available in India. It can be shipped across India, including Delhi, Kolkata, Surat, Jaipur, Noida, Gurgaon (Gurugram), Punjab, Chandigarh, Bhubaneswar, Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura, Sikkim, Kanpur, Lucknow, Dehradun, Shimla, Ahmedabad, Jodhpur, Mumbai, Aurangabad, Pune, Bengaluru, Hyderabad, Chennai, Visakhapatnam, Coimbatore, and other regions of India.
Note: South Delhi Pharma, act as a facilitation partner and do not manufacture, sell, or distribute pharmaceutical products. All facilitation activities are conducted in accordance with applicable Indian pharmaceutical and trade regulations.
